Overview Nepafenac Once Daily for Macular Edema - Study 1 Status: Completed Trial end date: 2015-05-01 Target enrollment: Participant gender: Summary The purpose of this study is to demonstrate superiority of Nepafenac Ophthalmic Suspension, 0.3% dosed once daily relative to Nepafenac Vehicle based upon clinical outcomes among diabetic subjects following cataract surgery. Phase: Phase 3 Details Lead Sponsor: Alcon ResearchTreatments: MethylprednisoloneMethylprednisolone AcetateMethylprednisolone HemisuccinateNepafenacPrednisolonePrednisolone acetatePrednisolone hemisuccinatePrednisolone phosphate